

Laron Syndrome

[View the current Laron Syndrome InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Laron_Syndrome.html)

(http://www.bioportfolio.com/indepth/Laron_Syndrome.html)



Recent Publications on Laron Syndrome:

- [Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.](#)
*BACKGROUND: Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to...*13th August, 2008
University of Cambridge, Department of Paediatrics, Addenbrookes Hospital,- Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):311-24. ([DOI Direct Link](#))
- [Statement 6: patients who are unresponsive to GH therapy should be given a trial of IGF-I.](#)
*In this article, a novel technique for the treatment of ruptured abdominal...*29th July, 2008
Division of Endocrinology, Metabolism & Diabetes, Department of- *Pediatr Endocrinol Rev.* 2008 Apr;5 Suppl 3:857-60.
- [Statement 5: the first line of treatment for children with idiopathic short stature \(ISS\) and low serum insulin-like growth factor-I \(IGF-I\) should be IGF-I.](#)
*In this article, a novel technique for the treatment of ruptured abdominal...*29th July, 2008
Department of Pediatrics, Cincinnati Children's Hospital Medical Center,- *Pediatr Endocrinol Rev.* 2008 Apr;5 Suppl 3:853-6.
- [Statement 3: a low serum IGF-I Level in idiopathic short stature patients indicates partial GH insensitivity.](#)
*In this article, a novel technique for the treatment of ruptured abdominal...*29th July, 2008
Pediatric Endocrinology Unit, Karolinska Institute & University Hospital- *Pediatr Endocrinol Rev.* 2008 Apr;5 Suppl 3:841-6.
- [ERRATUM: I. Hershkovitz, L. Kornreich, Z. Laron \(2007\) Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity \(Laron syndrome\). Am. J. Phys. Anthropol. 134:198-208.](#)
*In this article, a novel technique for the treatment of ruptured abdominal...*27th May, 2008
- *Am J Phys Anthropol.* 2008 Jul;136(3):373. ([DOI Direct Link](#))
- [Insulin-like growth factor-I treatment of children with Laron syndrome \(primary growth hormone insensitivity\).](#)
*Laron syndrome (LS, congenital primary GH insensitivity) is caused by...*17th May, 2008
Endocrinology and Diabetes Research Unit, Schneider Children's Medical- *Pediatr Endocrinol Rev.* 2008 Mar;5(3):766-71.
- [Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.](#)
*OBJECTIVE: To compare foot length deficits between patients with Laron...*13th May, 2008
Endocrinology and Diabetes Research Unit, Schneider Children's Medical- *J Pediatr Endocrinol Metab.* 2007 Dec;20(12):1325-8.

- [Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report.](#)
*BACKGROUND: There is little information on the relationship between growth...*9th May, 2008
Endocrinology and Diabetes Research Unit, Schneider Children's Medical- Growth Horm IGF Res. 2008 Oct;18(5):434-8. Epub 2008 May 6. ([DOI Direct Link](#))
- [Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism.](#)
*Growth hormone (GH) is involved in growth, and fat and carbohydrate...*1st May, 2008
Faculty of Engineering, Marmara University, Istanbul.- J Pediatr Endocrinol Metab. 2008 Jan;21(1):47-58.
- [\[New molecular mechanisms of growth hormone insensitivity\]](#)
*Growth hormone (GH), secreted by the anterior pituitary into the...*29th April, 2008
Service d'endocrinologie pediatrique, hopital des enfants, place du- Arch Pediatr. 2008 Feb;15(2):179-88. Epub 2008 Jan 18. ([DOI Direct Link](#))
- [The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency.](#)
*Primary or secondary IGF1 deficiency has been implicated in shortening of...*24th April, 2008
Endocrinology and Diabetes Research Unit, Schneider Children's Medical- Hormones (Athens). 2008 Jan-Mar;7(1):24-7.
- [Growth hormone \(GH\) insensitivity and insulin-like growth factor-I deficiency in Inuit subjects and an Ecuadorian cohort: functional studies of two codon 180 GH receptor gene mutations.](#)
*CONTEXT: Among more than 250 cases of GH insensitivity syndrome (GHIS)...*16th April, 2008
Department of Pediatrics, NRC5, Oregon Health and Science University, 3181- J Clin Endocrinol Metab. 2008 Mar;93(3):1030-7. Epub 2007 Dec 11. ([DOI Direct Link](#))
- [Lessons from the genetics of laron syndrome.](#)
*In the decade since the cloning and sequencing of the growth hormone...*15th April, 2008
Department of Pediatrics, University of Florida College of Medicine,- Trends Endocrinol Metab. 1998 Sep;9(7):276-83.
- [Serum ghrelin concentrations are increased in children with growth hormone insensitivity and decrease during long-term insulinlike growth factor-I treatment.](#)
*BACKGROUND: Ghrelin increases food intake, body weight, and growth hormone...*26th March, 2008
Department of Pediatrics, Division of Endocrinology, The University of- J Investig Med. 2008 Jan;56(1):26-31. ([DOI Direct Link](#))

Laron Syndrome Clinical Trials:



- [IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insensitivity Syndrome \(GHIS\) Such as Laron Syndrome](#)
Growth Hormone Insensitivity Syndrome (GHIS); Laron Syndrome



Laron Syndrome Patents:

- 5565428- [Method of administration of IGF-I](#)
- 6284282- [Method of spray freeze drying proteins for pharmaceutical administration](#)
- 6348323- [Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots](#)
- 6420518- [Insulin-like growth factor agonist molecules](#)
- 6423693- [Growth hormone releasing hormone expression system and methods of use, including use in animals](#)
- 6506874- [IGF-I variants](#)
- 6509443- [IGF-I point variants](#)
- 6559122- [Formulated composition](#)
- 6608028- [Insulin-like growth factor agonist molecules](#)
- 6608031- [Insulin-like growth factor agonist molecules](#)
- 6251865- [Insulin-like growth factor agonist molecules](#)
- 6207640- [Treatment of partial growth hormone insensitivity syndrome](#)
- 5646113- [Treatment of partial growth hormone insensitivity syndrome](#)
- 5741776- [Method of administration of IGF-I](#)
- 5747273- [Immunoassay of total insulin-like growth factor binding protein-1](#)
- 5783556- [Formulated insulin-containing composition](#)
- 5824642- [Treatment of partial growth hormone insensitivity syndrome](#)
- 5948757- [High dose IGF-1 therapy](#)
- 6066464- [Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots](#)
- 6080911- [Mice models of growth hormone insensitivity](#)
- 6121416- [Insulin-like growth factor agonist molecules](#)
- 6620789- [Insulin-like growth factor agonist molecules](#)
- 6632794- [Insulin-like growth factor agonist molecules](#)
- 6750321- [Insulin-like growth factor agonist molecules](#)
- 6949349- [Insulin-like growth factor agonist molecules](#)
- 6998134- [Biologically active implants](#)
- 7041450- [Method for diagnosing GH deficiency](#)
- 7084240- [Crystallization of IGF-1](#)
- 7186686- [Formulated composition](#)
- 7238658- [Crystallization of IGF-1](#)
- 7258864- [Methods for treatment of insulin-like growth factor-1 \(IGF-1\) deficiency](#)
- 7297763- [Crystallization of IGF-1](#)
- 6743894- [Insulin-like growth factor agonist molecules](#)
- 6716586- [Insulin-like growth factor agonist molecules](#)
- 6635619- [Insulin-like growth factor agonist molecules](#)
- 6645775- [Insulin-like growth factor agonist molecules](#)
- 6677305- [Insulin-like growth factor agonist molecules](#)
- 6680298- [Insulin-like growth factor agonist molecules](#)
- 6683053- [Insulin-like growth factor agonist molecules](#)
- 6689751- [Insulin-like growth factor agonist molecules](#)
- 6693078- [Insulin-like growth factor agonist molecules](#)

- 6693079- [Insulin-like growth factor agonist molecules](#)
- 6713451- [Insulin-like growth factor agonist molecules](#)
- 7354769- [Crystallization of IGF-1](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

